Case Report: Intraocular metastatic melanoma
The use of combination intravitreous melphalan and bevacizumab was well-tolerated in 2 patients with cutaneous metastatic melanoma to the vitreous and retina, according to a case report.
These eyes are often difficult to treat due to the likelihood that they will develop neovascularization.
In this case report, 2 eyes of 2 patients with cutaneous melanoma metastatic to the vitreoretinal were treated with combination intravitreous melphalan (10-30 mcg) and bevacizumab (1.25 mg). Treatment was given sequentially during the same visit monthly. Disease was controlled at 7 and 12 months follow up in each case.
Neovascular glaucoma was reversed and vision improved in one eye of one case and stabilized vision without the development of neovascularization was achieved in the eye of the other patient after treatment.
No ocular adverse events were reported in either case.
Reference
Francis JH, Canestraro J, Abramson DH, et al. Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina. Am J Ophthalmol Case Rep. 2022;26:101519. doi: 10.1016/j.ajoc.2022.101519. PMID: 35464680; PMCID: PMC9020100.
